Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 22
HOS-213455 · Präparat HOS-155106
Cushing’s disease
In Cushing’s disease, the safety assessment of the intramuscular formulation was made based on
150 patients who received pasireotide in the phase III study G2304 (median duration of exposure:
57 weeks). Patients were randomised in a 1:1 ratio to receive starting doses of either 10 mg or 30 mg
pasireotide, with a possibility to up-titrate to a maximum dose of 40 mg every 28 days. The most
common adverse reactions (incidence ≥1/10) in the phase III study G2304 were hyperglycaemia,
diarrhoea, cholelithiasis and diabetes mellitus. The frequency and severity of adverse reactions tended
to be higher with the higher starting dose of 30 mg, but this was not consistent for all adverse
reactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage 07bc9dee7af0f5325bfbfe659f9c9c51495d9602871069b653f8b3da50475bd0 · Zeichen 980–1693 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 22
HOS-213456 · Präparat HOS-155106
Tabulated list of adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage d51c90b617391dca447a849e03c6ddac1785fb6a36da5cf3e36f8f60e5aed8a9 · Zeichen 1695–1730 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 22
HOS-213457 · Präparat HOS-155106
The adverse reactions in Table 1 include events reported in the pivotal studies with the intramuscular
formulation in patients with acromegaly and with Cushing’s disease. Adverse reactions are listed
according to MedDRA primary system organ class. Within each system organ class, adverse reactions
are ranked by frequency. Within each frequency grouping, adverse reactions are presented in the order
of decreasing seriousness. Frequencies were defined as follows: Very common (≥1/10); common
(≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); not known (cannot be estimated from the
available data).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage e8cee38331fe26dc090620c2f30a83c96123bff0923ba30b3a04ed76e1fb7f7b · Zeichen 1732–2330 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 22–23
HOS-213458 · Präparat HOS-155106
22
Table 1 Adverse reactions by preferred term for pasireotide intramuscular use
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage e0784f94610caf5b71325348e3c72613311a96a812ba5aca39aa508ebccd9c17 · Zeichen 2385–2470 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 23
HOS-213459 · Präparat HOS-155106
System Organ Very common Common Uncommon Not known
Class
Blood and Anaemia
lymphatic
system disorders
Endocrine Adrenal
disorders insufficiency*
Metabolism and Hyperglycaemia, Type 2 diabetes Diabetic
nutrition diabetes mellitus mellitus, glucose ketoacidosis
disorders tolerance
impaired,
decreased
appetite
Nervous system Headache,
disorders dizziness
Cardiac Sinus
disorders bradycardia*, QT
prolongation
Gastrointestinal Diarrhoea, Abdominal Steatorrhea
disorders nausea, distension, Faeces
abdominal pain* vomiting discoloured
Hepatobiliary Cholelithiasis Cholecystitis*,
disorders cholestasis
Skin and Alopecia, pruritus
subcutaneous
tissue disorders
General Fatigue* Injection site
disorders and reaction*
administration
site conditions
Investigations Glycosylated Amylase
haemoglobin increased,
increased, alanine prothrombin time
aminotransferase prolonged
increased,
aspartate
aminotransferase
increased,
gamma-
glutamyltransfera
se increased,
blood glucose
increased, blood
creatine
phosphokinase
increased, lipase
increased
* Grouped terms: Adrenal insufficiency includes adrenal insufficiency and blood cortisol
decreased. Sinus bradycardia includes bradycardia and sinus bradycardia. Abdominal pain
includes abdominal pain and abdominal pain upper. Injection site reaction includes injection
site pain, injection site nodule, injection site discomfort, injection site bruising, injection site
pruritus, injection site reaction, injection site hypersensitivity and injection site swelling.
Cholecystitis includes cholecystitis acute and cholecystitis chronic. Fatigue includes fatigue
and asthenia.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage cef26775caed037313118d6916fef4c26ed267cb3b999670f448ecde48c3bd5b · Zeichen 2473–5800 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 23–24
HOS-213460 · Präparat HOS-155106
23
Description of selected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage bbe6bb730c0017fecd45f9b11affe53c7f49477044c55db0a0f9a7004628a7c7 · Zeichen 5854–5899 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 24
HOS-213461 · Präparat HOS-155106
Glucose metabolism disorders
Acromegaly
In acromegaly patients elevated fasting glucose level was the most frequently reported
grade 3/4 laboratory abnormality in the two phase III studies. In study C2305, grade 3 elevated fasting
glucose levels were reported in 9.7% and 0.6% and grade 4 in 0.6% and 0% of acromegaly patients
treated with pasireotide intramuscular use and octreotide intramuscular use, respectively. In study
C2402, grade 3 elevated fasting glucose levels were reported in 14.3% and 17.7% of acromegaly
patients treated with pasireotide intramuscular use 40 mg and 60 mg respectively, and in no patients in
the active control group. Two cases of hyperglycaemia-related emergencies (diabetic ketoacidosis and
diabetic hyperglycaemic coma) were reported following a dose increase of pasireotide to 60 mg in
medical treatment naïve patients; one in a patient with untreated hyperglycaemia and HbA1c >8%
prior to initiation of pasireotide and the other in a patient with untreated hyperglycaemia and a fasting
plasma glucose of 359 mg/dl, respectively. In both studies, mean FPG and HbA1c levels peaked within
the first three months of treatment with pasireotide intramuscular use. In medically naïve patients
(study C2305), the mean absolute increase in FPG and HbA1c was similar at most of the time points
for all patients treated with pasireotide intramuscular use irrespective of baseline values.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage 2718de0bdd783f21cc6d7c8b2bbe34c488f53d7a163fb3ec1b7ada316fccea0e · Zeichen 5901–7315 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 24
HOS-213462 · Präparat HOS-155106
The degree and frequency of hyperglycaemia observed in the two pivotal studies in acromegaly
patients were higher with Signifor intramuscular use than with active control (octreotide intramuscular
use or lanreotide deep subcutaneous injection). In a pooled analysis of the two pivotal studies, the
overall incidence of hyperglycaemia-related adverse reactions was 58.6% (all grades) and 9.9% (CTC
Grade 3 and 4) for Signifor intramuscular use versus 18.0% (all grades) and 1.1% (CTC Grade 3 and
4) for the active control. In the pivotal study with patients inadequately controlled on another
somatostatin analogue, the proportion of patients not previously treated with anti-diabetic agents who
required commencement of anti-diabetic therapy during the study was 17.5% and 16.1% in the
Signifor 40 mg and 60 mg arms compared to 1.5% in the active control arm. In the pivotal study with
patients who did not receive prior medical treatment, the proportion of patients who required
commencement of anti-diabetic therapy during the study was 36% in the Signifor arm compared to
4.4% in the active control arm.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage 958a6559f85fdff84e0843761149b99363bfad5d1ff2ea7c66892a86834d5286 · Zeichen 7317–8423 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 24
HOS-213463 · Präparat HOS-155106
Cushing’s disease
In Cushing’s disease patients, elevated FPG levels was the most frequently reported CTC Grade 3
laboratory abnormality (14.7% of patients) in the phase III study G2304; with no cases of Grade 4
reported. Mean HbA1c increases were less pronounced in patients with normal glycaemia at study
entry in comparison to pre-diabetic patients or diabetic patients. Mean FPG levels commonly
increased within the first month of treatment with decreases and stabilisation observed in subsequent
months. FPG and HbA1c increases were dose-dependent, and values generally decreased following
pasireotide intramuscular use discontinuation but remained above baseline values. The overall
incidence of hyperglycaemia-related adverse reactions was 75.3% (all grades) and 22.7% (CTC
Grade 3). Adverse reactions of hyperglycaemia and diabetes mellitus led to study discontinuation in 3
(2.0%) and 4 patients (2.7%), respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage 359d35bce3dcaed7557ed367ad1ec9419abce79e436e0f84f6cd4288f4e210d2 · Zeichen 8425–9351 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 24
HOS-213464 · Präparat HOS-155106
The elevations of fasting plasma glucose and HbA1c observed with pasireotide intramuscular use
treatment are reversible after discontinuation.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage 2451a90e5a245819dcf531ecd2efc4e37d0df5ce3f92c4805061c820841aa539 · Zeichen 9353–9495 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 24
HOS-213465 · Präparat HOS-155106
Monitoring of blood glucose levels in patients treated with Signifor is recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage 8e7bef2468b6eb66cfa5ddb59a2f1c985a24c487e99e6737713b8e09899054ae · Zeichen 9497–9599 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 24
HOS-213466 · Präparat HOS-155106
Gastrointestinal disorders
Gastrointestinal disorders were frequently reported with Signifor. These reactions were usually of low
grade, required no intervention and improved with continued treatment. In acromegaly patients,
gastrointestinal disorders were less frequent in inadequately controlled patients compared to medically
naïve patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage c9a3ed86c946332b8b419ac7f7074f7b95d3d72ef1a570ca90e0e485a8232f8e · Zeichen 9601–9945 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 24–25
HOS-213467 · Präparat HOS-155106
24
Injection site reactions
In the phase III studies, injection site related reactions (e.g. injection site pain, injection site
discomfort) were mostly grade 1 or 2 in severity. The incidence of such events was highest in the first
3 months of treatment. In the acromegaly studies, the events were comparable between pasireotide
intramuscular use and octreotide intramuscular use treated patients, and were less frequent in
inadequately controlled patients compared to medically naïve patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage 7deaf33fc0459791dd695640095040af6f125f573071c8a62d2e3211dc4c97a2 · Zeichen 10000–10496 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 25
HOS-213468 · Präparat HOS-155106
QT prolongation
In the acromegaly study C2305, the proportion of patients with newly occurring notable QT/QTc
intervals was comparable between pasireotide intramuscular use and octreotide intramuscular use
groups up to crossover, with few notable outlying values. QTcF >480 ms was reported for 3 versus
2 patients in the pasireotide intramuscular use and octreotide intramuscular use groups, respectively,
and QTcF >60 ms prolonged from baseline was reported for 2 versus 1 patients in the respective
groups. In study C2402, the only notable outlier was a QTcF value >480 ms in 1 patient in the
pasireotide intramuscular use 40 mg group. In the Cushing’s disease study G2304, a QTcF value
>480 ms was reported for 2 patients. No QTcF values >500 ms were observed in any of the pivotal
studies.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage c2038263d1bd0912508cca052dfab0436eced88ed21308d3b84c369ce1a71f20 · Zeichen 10498–11291 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 25
HOS-213469 · Präparat HOS-155106
Liver enzymes
Transient elevations in liver enzymes have been reported with the use of somatostatin analogues and
were also observed in healthy subjects and patients receiving pasireotide in clinical studies. The
elevations were mostly asymptomatic, of low grade and reversible with continued treatment. A few
cases of concurrent elevations in ALT greater than 3 x ULN and bilirubin greater than 2 x ULN have
been observed with the subcutaneous formulation, however not in patients treated with pasireotide
intramuscular use. All observed cases of concurrent elevations were identified within ten days of
initiation of treatment. The patients recovered without clinical sequelae and liver function test results
returned to baseline values after discontinuation of treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage 1e899bdaf608f2c0cc2b805dcfc1d79a5c551c95028c87b60ae4e573f84bfc2c · Zeichen 11293–12067 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 25
HOS-213470 · Präparat HOS-155106
Monitoring of liver enzymes is recommended before and during treatment with Signifor (see
section 4.4), as clinically appropriate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage fde302b2a847070fbfb9a94337ffb7273ea73be03176dc3ff8522ac915d01b15 · Zeichen 12069–12199 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 25
HOS-213471 · Präparat HOS-155106
Pancreatic enzymes
Asymptomatic elevations in lipase and amylase were observed in patients receiving pasireotide in
clinical studies. The elevations were mostly low grade and reversible while continuing treatment.
Pancreatitis is a potential adverse reaction associated with the use of somatostatin analogues due to the
association between cholelithiasis and acute pancreatitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage 963d410900ad556b79415652303db272715bff1a06c9db57135abd5fb0a8179a · Zeichen 12201–12579 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 25
HOS-213472 · Präparat HOS-155106
Reporting of suspected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage 822da43363cee11e87abeb55cf82453415269315377df150bb5de7dde8dd938f · Zeichen 12581–12621 im Abschnitt
Nebenwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.8 · PDF-Seite 25
HOS-213473 · Präparat HOS-155106
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage 591ce3aa6d6555db7032d0551da929e990b92080da2928085827a75c666ec353 · Zeichen 12623–12937 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.